Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides pteronyssinus (glutaraldehyde-modified) + dermatophagoides farinae (glutaraldehyde-modified)
- Development stage
- Unknown
- Lead developer
- Probelte Pharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This drug is a combination of glutaraldehyde-modified allergen extracts, known as allergoids, derived from the house dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. Developed by Probelte Pharma, it is indicated for allergen immunotherapy (AIT) in patients suffering from allergic rhinitis and allergic rhinoconjunctivitis triggered by house dust mite exposure. The glutaraldehyde modification process cross-links the allergen proteins, which significantly reduces their IgE-binding capacity (allergenicity) while preserving the essential T-cell epitopes (immunogenicity). This modification enhances the safety profile by reducing the risk of systemic allergic reactions during administration, allowing for a more rapid up-dosing schedule. The therapeutic mechanism involves shifting the patient's immune response from a Th2-dominated allergic profile to a Th1 and Regulatory T-cell (Treg) profile, characterized by the induction of IL-10 and the production of allergen-specific 'blocking' antibodies, particularly IgG4.
- Brand names
- Acarovac PlusAcarovac Quattro
- Other names
- D. pteronyssinus/D. farinae allergoidHouse dust mite allergoidModified house dust mite extract
02
Targets
IgE (Immunoglobulin E)sIgG4 (Allergen-specific immunoglobulin G4)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on dermatophagoides pteronyssinus (glutaraldehyde-modified) + dermatophagoides farinae (glutaraldehyde-modified).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides pteronyssinus (glutaraldehyde-modified) + dermatophagoides farinae (glutaraldehyde-modified).